LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension Associated With HFpEF

Interventions

DRUG: TNX-103
DRUG: Placebo

Sponsor

Tenax Therapeutics, Inc.